Medical Marijuana Market Size, Share, By Product Type (Oil, Capsules, Tinctures, and Others), Application (Cancer, Chronic Pain, Depression and Anxiety, Arthritis, Alzheimer’s disease, and Others), and Region - Trends, Analysis, and Forecast till 2035

• The medical marijuana market size is expected to grow at a valuation of USD 130.1 Billion by 2035.
• In 2024, the market valuation was USD 17.7 Billion.
• The target market is projected to expand at a CAGR of 22.8%.

The use of marijuana to treat medical problems is referred to as medicinal marijuana or medical cannabis, and the plant Cannabis Sativa is the source of it. Increased legalization, research, and demand for alternative therapies are factors driving the medical marijuana market growth. In addition to this, medical marijuana aids in pain management, appetite stimulation, nausea, and vomiting relief, and provides mental health benefits, further propelling the medical marijuana market growth.

The market is also driven by decreasing dependency on opioids, the presence of alternative forms of consumption, relief in severe chronic pain, help in treating multiple sclerosis and muscle spasms, improvement in sleep, increasing appetite, and decreasing weight loss, further contributing to the market expansion.

Generative AI Impact on Medical Marijuana Market:

• Second-generation AI systems handle response heterogeneity within and across subjects and concentrate on the result of a particular patient.  It is anticipated that the usage of digital medical marijuana would enhance product standardization, optimize therapeutic effects, lower healthcare expenses, and boost business profits, thus driving medical marijuana market growth.

Key Drivers of Target Market:

Medical Marijuana Aids in Chronic Pain Relief is Propelling Market Expansion

Chronic pain relief is one of the main factors driving the growth of the medical marijuana market as it is widely regarded as one of the most common reasons people look for medical marijuana. Many patients report that using marijuana significantly reduces pain, which creates a high demand for marijuana products marketed specifically for pain management. This demand is further fueled by the growing recognition of marijuana as a viable alternative to traditional pain medications, particularly when treating chronic conditions where other treatments may not be effective.

• For instance, in February 2025, Patients enrolled in Minnesota’s medical cannabis program found a noticeable change in pain relief within four months of receiving medical marijuana, according to a new study conducted by researchers at the Minnesota Office of Cannabis Management (OCM). The new report highlights data from patient enrollment, medical cannabis purchases, symptom, and side-effect ratings at the time of each purchase, and survey results to describe the experiences of patients who qualify for one of the chronic pain-related medical conditions.

Restraints:

Regulatory Complexities Faced by Medical Marijuana is Restricting the Market Expansion

The expansion of the medicinal marijuana market is hampered by complicated regulations and uneven legalization in different areas. Businesses have difficulties as a result of disparate state and federal policies, which restrict investment and research. Strict compliance regulations also raise operating expenses. This regulatory ambiguity deters expansion and new market participants.

• Counterbalance Statements: A stable market environment can be produced by harmonizing national and international legislation. Standardized regulations and legality based on research will increase market expansion and investor trust.

Opportunities:

Advancements in Medical Marijuana can Fuel the Market Expansion

Future treatments for liver disease may include cell therapy, such as macrophage immune cells, mesenchymal stem cells, and gene therapy to treat genetic liver disease, targeted therapies for treating cirrhosis, dietary changes, such as the Mediterranean diet or calorie-restricted diet, and certain lifestyle changes. These future advancements in the treatment of liver diseases can help improve the quality of life of people and prevent death, thereby fueling market growth. 

• For instance, in June 2024, MediPharm Labs Corp., a pharmaceutical company specializing in precision-based cannabinoids, entered into a licensing agreement with Remidose Aerosols (Remidose) to acquire the exclusive rights for advanced cannabis or marijuana products. MediPharm planned to use its existing GMP infrastructure, customer channels, and wellness sales expertise to expand the customer base of these advanced products in Canada and globally.

The market is segmented into product type, application, and region.

Product Type

Based on product type, the market is divided into oil, capsules, tinctures, and others. The oil segment is attributed to hold a dominant medical marijuana market share. The segment’s expansion is burgeoning due to the versatility in consumption, precise dosage control, high bioavailability, the growing medicinal use, and the growing legalization of cannabis oil. 

• For instance, in October 2024, Aurora Cannabis Inc., the Canadian based global leader in medical cannabis, in conjunction with MedReleaf Australia, announced an enhanced product range of premium medical cannabis oil in Australia. This expansion reinforced Aurora's dedication to providing high-quality, innovative cannabis solutions to patients around the world.

Application

Under application, the market is sub-segmented into cancer, chronic pain, depression and anxiety, arthritis, Alzheimer’s disease, and others. The chronic pain segment is expected to dominate the medical marijuana market due to its potential analgesic effects and perceived lower risk of addiction than other pain management options, it is the most frequently reported qualifying condition for medical cannabis use.

• For instance, in January 2023, Scientists at the University of Sydney had been awarded USD 1.7 million from NSW Health to research a new treatment for chronic pain which commonly affected people with spinal cord injuries. Up to 80 percent of people with a spinal cord injury developed some degree of persistent pain. A specific type of pain known as neuropathic pain is caused by damage to the spinal cord.

Regional Insights:

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa are the regions in which the market is studied.

North America: North America is projected to be the most dominant region in the medical marijuana market, with an estimated share of approximately 74%. The region’s dominance is driven by the legalization efforts in several states and provinces, growing public acceptance of medical marijuana, a well-established healthcare infrastructure, and extensive research and development into the medical applications of marijuana.

• For instance, in January 2024, Aurora Cannabis Inc., the Canadian-based leading global medical cannabis company, announced the launch of three new cannabis-infused beverages, available exclusively at first to veteran patients. Designed to deliver on taste, potency and choice, the introduction of beverages was in response to the needs of patients looking for alternative forms of cannabis to support the wellbeing of the patients.

Europe: The medical marijuana market in Europe is expected to grow at the highest rate during the forecast period. This is due to the progressive legislation of medical marijuana in many European countries, increasing public acceptance of its therapeutic potential, growing research into cannabinoid treatments, and a large patient population that could benefit from medical marijuana.

• For instance, in January 2025, Tilray Medical, a division of Tilray Brands, Inc., announced that its German subsidiary, Tilray Deutschland GmbH, had secured a tender to supply Luxembourg with its high-quality cannabis flower. The granting of this tender by the Ministry of Health and Social Security for the Grand Duchy of Luxembourg highlighted the trust placed in Tilray Medical to deliver high-quality medical marijuana on a consistent basis across the global medical marijuana industry.

Medical Marijuana Market Report Scope:

Segmentation:

By Product Type:

• Oil
• Capsules
• Tinctures
• Others

By Application:

• Cancer
• Chronic Pain
• Depression and Anxiety
• Arthritis
• Alzheimer’s Disease
• Others

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Indonesia
  • Malaysia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of the Middle East & Africa

The companies operating in the medical marijuana market are HempMeds, Avata Biosciences Inc., Neurotech International, GEOCANN, Akseera Pharma Corp, and others. The key players are adopting strategies including increasing awareness, reducing stigma, investing in marketing, and increasing research for the diversification of the market.

Medical Marijuana Market Companies:

• HempMeds
• Avata Biosciences Inc.
• Neurotech International
• GEOCANN
• Akseera Pharma Corp
• Aurora
• CannabisNL
• Curaleaf
• Green Thumb Industries
• Verano
• PANAXIA
• Tilray Europe
• TerrAscend

View an Additional List of Companies in the Medical Marijuana Market

• In January 2025, Aurora Cannabis Inc., the Canadian-based leading global medical cannabis company, announced the launch of the company's first German-cultivated medical cannabis product, under the brand IndiMed. Manufactured at Aurora's leading EU-GMP facility in Leuna, Germany, the new brand offered a supply of high-quality, locally grown and sold, medical marijuana for the country's expanding patient base.
• In January 2023, researchers at the European Molecular Biology Laboratory, had investigated the interaction between D9-tetrahydrocannabinol (THC), a component of marijuana and some proteins it might bind to. In a recent study, the researchers showed in vitro that THC inhibited an important human enzyme called autotaxin. This enzyme was involved in many different cellular functions, specifically producing a molecule called lysophosphatidic acid (LPA), which stimulates cell proliferation.

Analyst View:

Legalization, research, and the need for alternative medicines are driving growth in the medical marijuana market.  In addition to reducing opioid dependency, it provides pain management, hunger stimulation, nausea alleviation, mental health advantages, and seizure disorders.  It also contributes to market diversification by helping with weight loss, hunger stimulation, sleep enhancement, muscular spasms, and multiple sclerosis.

More Related Reports

Medical Air Conditioners Market
Medical Gases and Equipment Market
Medical Holography Market
Medical Imaging Information System Market
Medical Imaging Equipment Market